As noted in 2022 American College of Cardiology/American Heart Association guidelines, renal dysfunction increases the risk for toxicities of heart failure therapies and can impair response to diuretics. The management of heart failure in patients with CKD remains challenging and may require a multidisciplinary approach.
Therapy with SGLT2 inhibitors has been associated with improvements in mortality and hospitalization among patients with heart failure and advanced CKD (estimated glomerular filtration rate as low as 20 mL/min per 1.73 m2 ). According to Jhund and colleagues, the PIVOTAL trial showed that the high-dose iron therapy was superior to low-dose iron therapy for reducing heart failure hospitalizations in patients with end-stage renal disease on dialysis.
Learn more about the latest guidelines for the management of heart failure.
Medscape © 2023 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Patrick Rossignol. Fast Five Quiz: Chronic Kidney Disease and Heart Failure - Medscape - Feb 03, 2023.